MRSN Mersana Therapeutics Inc.

5.26
-0.57  -10%
Previous Close 5.83
Open 5.58
Price To Book 3.06
Market Cap 238,961,721
Shares 45,429,985
Volume 571,387
Short Ratio
Av. Daily Volume 476,055
Stock charts supplied by TradingView

NewsSee all news

  1. Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study

    - Well tolerated at doses up to 43 mg/m2 with encouraging activity in heavily pre-treated patient populations - Favorable trend towards higher response rates with higher NaPi2b expression - On track for interim

  2. Mersana Therapeutics to Report Updated Data from the XMT-1536 Phase 1 Dose Escalation Study

    CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

  3. Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates

    XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women's Cancer XMT-1536 interim Phase 1 dose expansion

  4. Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2019 Financial Results and Business Updates

    CAMBRIDGE, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

  5. Mersana Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Development to be discontinued - noted January 4, 2019.
XMT1522
HER2 - breast cancer
Phase 1 interim dose expansion data to be presented in 2Q 2020 with more mature data expected in 2H 2020.
XMT-1536
Ovarian Cancer, Non Small Cell Lung Cancer
Phase 1 trial to be initiated 1H 2020.
XMT-1592

Latest News

  1. Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study

    - Well tolerated at doses up to 43 mg/m2 with encouraging activity in heavily pre-treated patient populations - Favorable trend towards higher response rates with higher NaPi2b expression - On track for interim

  2. Mersana Therapeutics to Report Updated Data from the XMT-1536 Phase 1 Dose Escalation Study

    CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

  3. Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates

    XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women's Cancer XMT-1536 interim Phase 1 dose expansion

  4. Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2019 Financial Results and Business Updates

    CAMBRIDGE, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

  5. Mersana Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates

  6. Mersana Therapeutics Announces Pipeline Updates and 2020 Strategic Priorities and Milestones

    XMT-1536 On Track to Demonstrate Proof of Concept in Both Ovarian and Non-Small Cell Lung Cancer with Multiple Data Readouts Expected Throughout 2020 XMT-1536 Expansion Study Dose Increased; Dose Escalation Study

  7. Mersana Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates

  8. Mersana Therapeutics Presents New Preclinical Data from Immunosynthen Platform at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

    CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates

  9. Mersana Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Updates

    XMT-1536 Expansion Study Continues According to Plan Ended Third Quarter 2019 with $112 Million Available to Fund the Advancement of Multiple Product Candidates CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) --

  10. Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2019 Financial Results and Business Updates

    CAMBRIDGE, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates

  11. Mersana Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates

  12. Mersana Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates